Complete response to chemoimmunotherapy in a patient with metastatic squamous cell non-small cell lung cancer: A case report

Non-small cell lung cancer (NSCLC) is a common type of malignant neoplasm that is the leading cause of cancer death worldwide. In the Russian Federation, according to statistical reports, there is also an increase in morbidity. Squamous cell histological variant of NSCLC is detected in 25–30% of lung cancer cases and belongs to unfavorable subtype. More than 10 years ago, chemotherapy was approved the treatment for metastatic squamous cell NSCLC only. In the era of checkpoint inhibitors, the number of treatment options for NSCLC has increased. The results of a double-blind, randomized, placebo-controlled phase III trial of KEYNOTE-407 showed undoubtedly better efficacy of the combination of pembrolizumab + chemotherapy compared with chemotherapy and placebo in patients with metastatic squamous cell carcinoma in terms of median progression-free survival –8.0 versus 5.1 months and median overall survival – 17.1 versus 11.6 months. This article presents a clinical observation efficacy combination of pembrolizumab and standard chemotherapy for the treatment of metastatic squamous cell NSCLC with high tumor burden. A significant reduction in disease symptoms and partial response were recorded after two courses of chemoimmunotherapy. Complete response achieved after four courses. Maintenance therapy with pembrolizumab was prescribed. According to the results of chest CT scans in March 2025, a complete response was maintained. Combination of pembrolizumab and chemotherapy in real clinical practice of therapy of a patient with a big tumor burden of squamous cell NSCLC demonstrates high efficacy in the treatment.

1. Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693. https://doi.org/10.1016/j.canep.2024.102693.

2. Каприн АД, Старинский ВВ, Шахзадова АО (ред.). Состояние онкологической помощи населению России в 2023 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2024. 262 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2024/06/sop-2023-elektronnaya-versiya.pdf.

3. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021;39(21):2339–2349. https://doi.org/10.1200/JCO.21.00174.

4. Kersten K, Salvagno C, de Visser KE. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol. 2015;6:516. https://doi.org/10.3389/fimmu.2015.00516.

5. Galluzzi L, Zitvogel L, Kroemer G. Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunol Res. 2016;4(11):895–902. https://doi.org/10.1158/2326-6066.CIR-16-0197.

6. Laktionov KK, Artamonova EV, Breder VV, Gorbunova VA, Demidova IA, Dengina NV et al. Non-small cell lung cancer. RUSSCO Practical Guidelines, Part 1.1. Malignant Tumors. 2024;14(3s2):65–104. (In Russ.) https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-04.

7. Pardoll DM. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. https://doi.org/10.1038/nrc3239.

8. Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I et al. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019;14(1):25–36. https://doi.org/10.1016/j.jtho.2018.09.006.

9. Gómez-López S, Whiteman ZE, Janes SM. Mapping lung squamous cell carcinoma pathogenesis through in vitro and in vivo models. Commun Biol. 2021;4(1):937. https://doi.org/10.1038/s42003-021-02470-x.

10. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. https://doi.org/10.1016/S1470-2045(16)30498-3.

11. Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32(7):881–895. https://doi.org/10.1016/j.annonc.2021.04.008.

12. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol. 2022;17(3):362–387. https://doi.org/10.1016/j.jtho.2021.11.003.

13. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3(8):819–831. https://doi.org/10.1097/JTO.0b013e31818020eb.

14. Sankar V, Kothai R, Vanisri N, Akilandeswari S, Anandharaj G. Lung cancer – a review. Int J Health Sci Res. 2023;13(10):307–315. https://doi.org/10.52403/ijhsr.20231042.

15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. https://doi.org/10.3322/caac.21254.

16. Fernández-Trujillo L, Garcia-Robledo JE, Zúñiga-Restrepo V, Sua LF. Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series. Respir Med Case Rep. 2020;30:101114. https://doi.org/10.1016/j.rmcr.2020.101114.

17. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–499. https://doi.org/10.1038/ni.2035.

18. Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q et al. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Front Immunol. 2021;11:622509. https://doi.org/10.3389/fimmu.2020.622509.

19. Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999–2006. https://doi.org/10.1200/JCO.22.01990.

20. Liu SV, Rai P, Wang D, Hu X, Schwarzenberger PO. First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices. JTO Clin Res Rep. 2022;4(2):100444. https://doi.org/10.1016/j.jtocrr.2022.100444.